At 52 weeks, the semaglutide group showed a statistically significant reduction in areal bone mineral density at the total hip (estimated treatment difference: -0.020 g/cm, p = 0.001, equating to approximately 2.6% loss) and at the lumbar spine (ETD: -0.018 g/cm, p = 0.007, approximately 2.1% loss)
(2024) 16:1759720x241271886
5-8 In this regard, it is well recognised that the secretion and action of GIP and GLP-1 is disturbed in obesity and T2D, 5-10,16-18 which could also directly impact skeletal health
If you are using a compounded GLP-1, check where your provider is sourcing it
PlexusDx simplifies this process by offering direct-to-patient GLP-1 therapy without insurance requirements, membership fees, or prior authorization delays
2025;doi:10.1111/dom.16152